MedTrace Logo

Phase III Trial of Adjuvant Chemo-radiotherapy After D2 Surgery of Gastric Cancer

NCT03601988 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 408

Last updated 2018-07-26

No results posted yet for this study

Summary

The purpose of this study is to explore the efficacy of adjuvant radiotherapy for D2 resected gastric cancer

Conditions

Interventions

RADIATION

Concurrent chemo-radiotherapy

Experimental group receive 6 cycles of XELOX chemotherapy and concurrent chemo-radiotherapy. The radiotherapy dose of 45Gy in 25 fractions delivered by IMRT Radiotherapy

DRUG

Chemotherapy

Chemotherapy group receive 8 cycles of XELOX.

Sponsors & Collaborators

  • Huazhong University of Science and Technology

    lead OTHER

Principal Investigators

  • Xianglin Yuan, MD,PhD · Tongji Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-28
Primary Completion
2020-07-28
Completion
2022-07-28

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03601988 on ClinicalTrials.gov